vzphotos/iStock Editorial via Getty Images
- Health Canada has approved AbbVie’s (NYSE:ABBV) antibody-drug conjugate Elahere (mirvetuximab soravtansine) for ovarian cancer.
- The treatment is approved for women who have received one to three other therapies.
- More specifically, Elahere is approved for folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal
